David Lebovitz

Stock Analyst at Citigroup

(3.40)
# 980
Out of 5,030 analysts
91
Total ratings
68.18%
Success rate
10.48%
Average return

Stocks Rated by David Lebovitz

Alnylam Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $527$583
Current: $481.67
Upside: +21.04%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82$78
Current: $53.29
Upside: +46.37%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378$469
Current: $438.90
Upside: +6.86%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70$74
Current: $41.57
Upside: +78.01%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37$38
Current: $73.53
Upside: -48.32%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29$17
Current: $65.95
Upside: -74.22%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57$54
Current: $110.28
Upside: -51.03%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38$35
Current: $73.09
Upside: -52.11%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16$17
Current: $1.65
Upside: +930.30%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12$11
Current: $1.43
Upside: +669.23%
Maintains: Overweight
Price Target: $194$199
Current: $210.50
Upside: -5.46%
Maintains: Overweight
Price Target: $510$480
Current: $5.93
Upside: +7,994.44%